140 related articles for article (PubMed ID: 22081445)
21. [Effect of CD56 Expression on Prognosis of AML Patients with AML/ETO Mutation].
Zhao J; Zhang HT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):63-67. PubMed ID: 32027254
[TBL] [Abstract][Full Text] [Related]
22. [Clinical Features and Prognosis of 227 cases of Acute Myeloid Leukemia with Cross-lineage Antigen Expression].
Fang F; Zhu P; Zhang Y; Lu XZ; Dong YJ; Sun YH; Wang LH; Bu DF; Cen XN; Wang MJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):990-7. PubMed ID: 27531762
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.
Suzuki R; Murata M; Kami M; Ohtake S; Asou N; Kodera Y; Tomonaga M; Masaki Y; Kusumoto S; Takeuchi J; Matsuda S; Hirai H; Yorimitsu mS; Hamajima N; Seto M; Shimoyama M; Ohno R; Morishima Y; Nakamura S
Int J Hematol; 2003 Jun; 77(5):482-9. PubMed ID: 12841387
[TBL] [Abstract][Full Text] [Related]
25. Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia.
Zhang Y; Gu H; Chen Q; Zhang Y; Cheng H; Yang J; Wang J; Hu X
Acta Haematol; 2020; 143(1):9-18. PubMed ID: 31167182
[TBL] [Abstract][Full Text] [Related]
26. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
27. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis.
Juncà J; Garcia-Caro M; Granada I; Rodríguez-Hernández I; Torrent A; Morgades M; Ribera JM; Millá F; Feliu E
Ann Hematol; 2014 Sep; 93(9):1483-9. PubMed ID: 24782118
[TBL] [Abstract][Full Text] [Related]
28. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
29. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.
Prijić S; Ugrina I; Labar B; Nemet D; Batinić J; Zadro R; Ries S; Gjadrov-Kuvedžić K; Davidović S; Batinić D
Leuk Lymphoma; 2015; 56(8):2281-8. PubMed ID: 25426669
[TBL] [Abstract][Full Text] [Related]
31. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
32. CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.
Fujiwara SI; Muroi K; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Ozawa K
Hematology; 2017 Jul; 22(6):347-353. PubMed ID: 28097942
[TBL] [Abstract][Full Text] [Related]
33. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
34. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.
Mann KP; DeCastro CM; Liu J; Moore JO; Bigner SH; Traweek ST
Am J Clin Pathol; 1997 Jun; 107(6):653-60. PubMed ID: 9169661
[TBL] [Abstract][Full Text] [Related]
35. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
36. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
39. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
40. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
